# Ipamorelin Research: Mechanism, the Human Data, and the Stack Evidence > Ipamorelin research in full: GHS-R1a selectivity, the ~2-hour human half-life, the failed Phase 2 ileus trial, rat bone-growth data, and the class-level synergy studies behind the CJC-1295 stack. Mechanism first, then the human anchors, then the class-level combination evidence — separated and cited. ## The gist Ipamorelin research comes down to one strong idea and a thin evidence base around it. The strong idea is selectivity: this peptide raises growth hormone cleanly, without the cortisol and prolactin spillover that older growth-hormone-releasing peptides caused [1]. That is genuinely well-established and reproducible. The thin part is everything downstream in humans. The peptide has a short half-life of about two hours in people [2], produces a single growth-hormone pulse, and — in the one real human trial — failed to beat placebo for the bowel condition it was tested on [3]. The most-searched topic, the CJC-1295 stack, has no trial of its own; its scientific support is borrowed from studies of related peptides combined with GHRH [7][8][13]. Below, the mechanism, the human numbers, and the synergy evidence are laid out in that order — and the monotherapy results are never blended into the combination claims. ## What is ipamorelin peptide, and what does it do Ipamorelin is a synthetic pentapeptide — a chain of five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The alpha-aminoisobutyric acid at position one and the D-form amino acids make it resist the enzymes that would otherwise chew it up. It was derived from the earlier peptide GHRP-1 by removing a central two-amino-acid segment. Functionally, it is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). What ipamorelin does: it binds GHS-R1a on pituitary somatotrophs (the cells that store and release growth hormone), triggering a calcium-driven pulse of growth-hormone release [1]. Because it hits the ghrelin receptor rather than the GHRH receptor, its pulse adds to — rather than overlapping with — the GHRH pathway, which is the mechanistic basis for combining it with a GHRH analog. Downstream, growth hormone can raise hepatic IGF-1, though short rodent studies often show no IGF-1 change, indicating the early effects are driven by the GH pulse itself rather than sustained IGF-1 elevation [4]. ## Selectivity is the headline finding The 1998 founding study is the anchor for everything. In primary rat pituitary cells, anaesthetized rats, and conscious swine, ipamorelin released growth hormone potently — swine ED50 of 2.3 ± 0.03 nmol/kg, comparable to GHRP-6 at 3.9 nmol/kg [1]. The distinguishing result was selectivity: even at more than 200 times its growth-hormone ED50, ipamorelin did not raise ACTH or cortisol above GHRH-induced levels [1]. That is why it carries the title "the first selective growth hormone secretagogue" — it decoupled growth-hormone release from the stress-hormone activation that defined the GHRP-6 generation. ## The human evidence is limited — and partly negative Two human datasets matter. The first is pharmacokinetic: in healthy male volunteers (n=8 per dose level, five 15-minute IV infusions of 4.21–140.45 nmol/kg), ipamorelin showed dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg, with the growth-hormone response peaking around 40 minutes as a single discrete pulse [2]. The second is the only efficacy trial. In the Phase 2 RCT for postoperative ileus (NCT00672074; 114 adults after bowel resection, 0.03 mg/kg IV twice daily for up to 7 days), ipamorelin missed its primary endpoint: median time to first tolerated meal was 25.3 hours versus 32.6 hours for placebo (p=0.15) [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% on placebo — no ipamorelin-specific safety signal in that short window, but no efficacy either [3]. ## Preclinical efficacy: bone, weight, and a 2024 update In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (three times daily, 15 days) raised longitudinal bone growth from 42 to 44, 50, and 52 micrometers/day dose-dependently, with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4] — a skeletal effect that tracked dose without moving the systemic IGF-1 marker. The freshest in-vivo finding is from 2024. In a ferret model, intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h) — but had no anti-emetic effect, in contrast to anamorelin, which cut acute emesis by 60% [5]. The weight-protective effect ran through a peripheral mechanism; the peptide did not stop the nausea pathway. ## The synergy evidence behind the stack The combination rationale rests on human and preclinical studies of related growth-hormone-releasing peptides paired with GHRH — not on ipamorelin itself. Co-administration of hexarelin (a GHRP) plus GHRH-(1-29) produced peak growth-hormone secretion significantly greater than the arithmetic sum of each alone — true synergism, p=0.001 — in healthy men, though the synergism faded with repeated boluses 60–120 minutes apart [8]. A 34-hour continuous GHRP-6 infusion in healthy men more than doubled integrated growth-hormone concentration versus saline and amplified the response to superimposed GHRH boluses [9]. A 30-day continuous GHRP-2 + GHRH infusion in older men and women drove greater pulsatile growth-hormone output than either agent alone, with sustained IGF-1, IGFBP-3, and IGFBP-5 and no tachyphylaxis [7]; chronic pre-treatment with either agent converted an additive response into a synergistic one [10]. And the usual partner, CJC-1295, produced 2- to 10-fold growth-hormone increases for six-plus days and 1.5- to 3-fold IGF-1 elevation after a single subcutaneous dose, while preserving pulsatile secretion [13]. Read together, these establish that GHRP + GHRH co-administration can exceed additive growth-hormone release — a class principle, applied to ipamorelin by extension, not by direct trial. ## Is ipamorelin fda approved No. Ipamorelin has never been approved as a drug for any indication by the FDA or any other regulatory authority [3]. It was investigated for postoperative ileus and reached one Phase 2 trial, which failed its primary endpoint [3]. A 2020 andrology review frames the broader gap between marketed use and approved indications for the growth-hormone-secretagogue class, noting how far promotion outruns evidence [11]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is also prohibited in sport at all times under the WADA category S2 and is detectable in urine by accredited laboratories. --- A trading-desk reading of the ipamorelin and combination-stack record — the selective GH pulse logged first as the one clean number, the CJC-1295 pairing read as class-level pharmacology rather than a tested product, and the failed human trial and missing long-term safety left openly unhedged; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.